Suppr超能文献

一名52岁女性在接种新冠病毒灭活疫苗(国药集团)加强针后出现单侧前巩膜炎:病例报告

Unilateral Anterior Scleritis Following the Booster Shot of Inactivated COVID-19 (Sinopharm) Vaccine in a 52-Year-Old Woman: A Case Report.

作者信息

Jazi Kimia, Rahimi Mahnaz, Hasani Fatemeh, Shirmohammadi Maryam, Masoumi Maryam

机构信息

Student Research Committee, Faculty of Medicine, Qom University of Medical Sciences, Qom, Iran.

Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.

出版信息

Case Rep Rheumatol. 2024 Dec 28;2024:6614757. doi: 10.1155/crrh/6614757. eCollection 2024.

Abstract

The only way to mitigate the spread of coronavirus disease 2019 (COVID-19) pandemic was vaccines. While effective in decreasing the rate and severity of the disease, there also have been considerable adverse events. Since the birth of vaccines, adverse reactions accompanied the immunity, and COVID-19 vaccines are no exceptions. This is a report about a 52-year-old female patient who presented with bilateral redness of the eyes, with normal bilateral visual acuity, postbooster dose of the Sinopharm COVID-19 vaccine. She had no significant past history of any disease or any similar reactions after previous doses. All her physical examinations were normal. Ophthalmic examination disclosed diffuse erythema, and mild scleral edema consistent with bilateral anterior diffused scleritis with negative phenylephrine test. Thereafter, with a course of tapering doses of prednisolone (30 mg at the onset) combined with azathioprine (100 mg/day), over a 2-week period, the condition completely resolved. Very few vaccination-related adverse events may manifest an unrecognized underlying autoimmune vasculopathy which may also require urgent management. As in this case, ocular adverse events, as highlighted, are highly associated with undiagnosed autoimmune diseases and therefore warrant careful assessment by clinicians.

摘要

减轻2019冠状病毒病(COVID-19)大流行传播的唯一方法是疫苗。虽然疫苗在降低疾病的发病率和严重程度方面有效,但也出现了相当多的不良事件。自疫苗诞生以来,不良反应就伴随着免疫反应,COVID-19疫苗也不例外。这是一份关于一名52岁女性患者的报告,该患者在接种国药集团COVID-19疫苗加强针后出现双眼发红,双眼视力正常。她既往没有任何重大疾病史,之前接种疫苗后也没有出现任何类似反应。她所有的体格检查均正常。眼科检查发现弥漫性红斑和轻度巩膜水肿,符合双侧前部弥漫性巩膜炎,苯肾上腺素试验阴性。此后,在2周的时间里,通过逐渐减少泼尼松龙剂量(开始时30毫克)并联合硫唑嘌呤(100毫克/天)的疗程,病情完全缓解。极少数与疫苗接种相关的不良事件可能表明存在未被识别的潜在自身免疫性血管病,这也可能需要紧急处理。就像这个病例一样,如所强调的,眼部不良事件与未确诊的自身免疫性疾病高度相关,因此临床医生需要仔细评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ddf/11699981/e1c80fba83f5/CRIRH2024-6614757.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验